Efficacy of Infusions of MSC From Wharton Jelly in the SARS-Cov-2 (COVID-19) Related Acute Respiratory Distress Syndrome

NCT04625738 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

COVID19 ARDS

Interventions

BIOLOGICAL: Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells
BIOLOGICAL: Placebo

Sponsor

Central Hospital, Nancy, France